TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03607513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64264681
Description: For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64264681
Description: For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-64264681 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-64264681 will be administered as oral solution.
Study: NCT01098149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BD and BVC, AFB
Description: Some patients are randomized into the AFB, the others into the BD and BVC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BD and BVC, AFB
Description: Some patients are randomized into the AFB, the others into the BD and BVC
Study: NCT03009877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
Study: NCT04651049

Intervention type: DRUG
Intervention: propranolol
Description: This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
Study: NCT00539149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxycillin
Description: 50 mg/kg/day twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo equivalent to amoxycillin
Description: 50 mg/kg/d twice daily
Study: NCT01210196

Intervention type: PROCEDURE
Intervention: MRI
Description: Cardiac MRI after 12 and 24 months.
Study: NCT00976469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)
Description: 2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)
Description: 2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011
Description: Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
Study: NCT01336881

Intervention type: GENETIC
Intervention: RNA analysis

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: nucleic acid sequencing

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study: NCT03298503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: task-priority strategies
Description: posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task-priority strategies
Description: posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray).
Study: NCT00519896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study: NCT05269784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
Description: Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
Description: Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
Study: NCT02139475

Intervention type: PROCEDURE
Intervention: Colonoscopy
Study: NCT03837392

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Assessment (18-26 weeks pregnant)
Description: At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Assessment (18-26 weeks pregnant)
Description: At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention and Phone Coaching Interventions
Description: ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Intervention and Phone Coaching Interventions
Description: ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum
Description: The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum
Description: The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow Up Assessments: 8 weeks postpartum
Description: The follow-up assessment at 8-weeks postpartum will be completed via phone.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Assessments: 8 weeks postpartum
Description: The follow-up assessment at 8-weeks postpartum will be completed via phone.
Study: NCT04170868

Intervention type: OTHER
Group type: OTHER
Intervention: ADHD Psycheducation
Description: The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.

Intervention type: OTHER
Group type: OTHER
Intervention: ADHD Psycheducation
Description: The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
Study: NCT01473381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone was supplied as film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone was supplied as film-coated tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to citalopram
Description: Placebo to citalopram was supplied as a capsule.
Study: NCT05031650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: openCPAP
Description: Randomized to : Individualized high level CPAP between 8-10 cmH2O pressure
Study: NCT01473381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to citalopram
Description: Placebo to citalopram was supplied as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to citalopram
Description: Placebo to citalopram was supplied as a capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to vilazodone
Description: Placebo to vilazodone was supplied as film-coated tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to vilazodone
Description: Placebo to vilazodone was supplied as film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to vilazodone
Description: Placebo to vilazodone was supplied as film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to vilazodone
Description: Placebo to vilazodone was supplied as film-coated tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram was supplied as encapsulated tablets.
Study: NCT02387216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: Investigational, fully human antibody targeting and inhibiting ErbB3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: approved chemotherapy treatment for NSCLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: approved chemotherapy treatment for NSCLC
Study: NCT02586337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study: NCT01335503

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AN-PEP
Description: Endoprotease enzyme (AN-PEP)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AN-PEP
Description: Endoprotease enzyme (AN-PEP)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AN-PEP
Description: Endoprotease enzyme (AN-PEP)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AN-PEP
Description: Endoprotease enzyme (AN-PEP)
Study: NCT02467322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascitic fluid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ascitic fluid
Study: NCT04678622

Intervention type: DEVICE
Intervention: Bioferula3D
Description: Custom splint with 3D technology classified as a custom medical device
Study: NCT02254837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver PTX Drug-Eluting Stent
Study: NCT00805493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Study: NCT00683280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Twice weekly brief counseling based on public health service guidelines for quitting smoking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Twice weekly brief counseling based on public health service guidelines for quitting smoking.
Study: NCT05031650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standardCPAP
Description: Randomized to : Standard level CPAP between 6-8 cmH2O pressure
Study: NCT00712881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin hydrochloride
Description: Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered per dose and schedule specified in the arm description.
Study: NCT02419729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser
Description: SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Topical estrogen cream treatment: Estriol 1mg daily.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Estrogen
Description: Topical estrogen cream treatment: Estriol 1mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Estrogen
Description: Placebo of topical estrogen cream.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo of CO2 laser
Description: SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
Study: NCT02043262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reablement
Description: The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
Study: NCT00712881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Free doxorubicin hydrochloride
Description: Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered per dose and schedule specified in the arm description.
Study: NCT01869699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 1 gram/100mLs intravenously administered over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
Study: NCT01767506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveillance and treatment with azithromycin of newcomer and traveler families
Description: The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
Study: NCT02043262

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The control intervention is standard home-based treatment/care in Norway.
Study: NCT01027364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor IX (rFIXFc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor IX (rFIXFc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor IX (rFIXFc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor IX (rFIXFc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFIX
Study: NCT00002757

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Study: NCT01767506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
Study: NCT03091192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously
Study: NCT00002757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study: NCT02501213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone (+/- Furosemide)
Description: Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
Study: NCT00985543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
Study: NCT02952664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUMP Monitoring
Description: A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
Study: NCT02394041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture with sham needles
Study: NCT02751736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CJLP243
Description: Perioperative administration till postoperative weeks 3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Perioperative administration till postoperative weeks 3
Study: NCT04076020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational agent/AliveCor Kardia - Intervention
Description: Use of the relational agent and Kardia daily for 120 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Use of the WebMD app daily for 120 days.
Study: NCT04538924

Intervention type: OTHER
Group type: OTHER
Intervention: extended clinical, laboratory and instrumental examination; treatment options comparison
Description: Multimodality investigation and different treatment comparison

Intervention type: OTHER
Group type: OTHER
Intervention: extended clinical, laboratory and instrumental examination; treatment options comparison
Description: Multimodality investigation and different treatment comparison